Zoetis Inc. (ZTS)

$168.18

-1.48

(-0.87%)

Market is closed - opens 7 PM, 21 Jun 2024
star icon

Zoetis Inc is a global animal health company that produces and markets vaccines, medicines, and diagnostics for pets and livestock.

Insights on Zoetis Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.21B → 2.19B (in $), with an average decrease of 1.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 525.0M → 599.0M (in $), with an average increase of 12.4% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 36.0% return, outperforming this stock by 37.0%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 31.7% return, outperforming this stock by 41.6%

Performance

  • $167.21
    $170.91
    $168.18
    downward going graph

    0.58%

    Downside

    Day's Volatility :2.17%

    Upside

    1.6%

    downward going graph
  • $144.80
    $200.89
    $168.18
    downward going graph

    13.9%

    Downside

    52 Weeks Volatility :27.92%

    Upside

    16.28%

    downward going graph

Returns

PeriodZoetis Inc.Sector (Health Care)S&P500
3 Months
-0.08%
0.5%
4.4%
6 Months
-13.6%
9.0%
15.3%
1 Year
-1.0%
11.3%
25.4%
3 Years
-9.87%
17.4%
29.5%

Highlights

Market Capitalization
77.4B
Book Value
$11.07
Dividend Share
1.557
Dividend Yield
1.02%
Earnings Per Share (EPS)
5.19
PE Ratio
32.69
PEG Ratio
2.58
Wall Street Target Price
212.29
Profit Margin
27.38%
Operating Margin TTM
36.58%
Return On Assets TTM
13.99%
Return On Equity TTM
50.05%
Revenue TTM
8.7B
Revenue Per Share TTM
19.0
Quarterly Revenue Growth YOY
9.5%
Gross Profit TTM
5.6B
EBITDA
3.6B
Diluted Eps TTM
5.19
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
5.76
EPS Estimate Next Year
6.38
EPS Estimate Current Quarter
1.34
EPS Estimate Next Quarter
1.51

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Zoetis Inc.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
19
18
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.23%

Current $168.18
Target $212.29

Company Financials

FY18Y/Y Change
Revenue
5.8B
↑ 9.76%
Net Income
1.4B
↑ 65.28%
Net Profit Margin
24.52%
↑ 8.24%
FY19Y/Y Change
Revenue
6.3B
↑ 7.47%
Net Income
1.5B
↑ 5.04%
Net Profit Margin
23.96%
↓ 0.56%
FY20Y/Y Change
Revenue
6.7B
↑ 6.63%
Net Income
1.6B
↑ 9.2%
Net Profit Margin
24.54%
↑ 0.58%
FY21Y/Y Change
Revenue
7.8B
↑ 16.49%
Net Income
2.0B
↑ 24.36%
Net Profit Margin
26.2%
↑ 1.66%
FY22Y/Y Change
Revenue
8.1B
↑ 3.91%
Net Income
2.1B
↑ 3.78%
Net Profit Margin
26.16%
↓ 0.04%
FY23Y/Y Change
Revenue
8.5B
↑ 5.74%
Net Income
2.3B
↑ 10.88%
Net Profit Margin
27.43%
↑ 1.27%
Q4 FY22Q/Q Change
Revenue
2.0B
↑ 1.9%
Net Income
461.0M
↓ 12.85%
Net Profit Margin
22.6%
↓ 3.82%
Q1 FY23Q/Q Change
Revenue
2.0B
↓ 1.96%
Net Income
552.0M
↑ 19.74%
Net Profit Margin
27.6%
↑ 5.0%
Q2 FY23Q/Q Change
Revenue
2.2B
↑ 9.0%
Net Income
671.0M
↑ 21.56%
Net Profit Margin
30.78%
↑ 3.18%
Q3 FY23Q/Q Change
Revenue
2.2B
↓ 1.33%
Net Income
596.0M
↓ 11.18%
Net Profit Margin
27.71%
↓ 3.07%
Q4 FY23Q/Q Change
Revenue
2.2B
↑ 2.88%
Net Income
525.0M
↓ 11.91%
Net Profit Margin
23.72%
↓ 3.99%
Q1 FY24Q/Q Change
Revenue
2.2B
↓ 1.04%
Net Income
599.0M
↑ 14.1%
Net Profit Margin
27.35%
↑ 3.63%
FY18Y/Y Change
Total Assets
10.8B
↑ 25.52%
Total Liabilities
8.6B
↑ 26.35%
FY19Y/Y Change
Total Assets
11.5B
↑ 7.13%
Total Liabilities
8.8B
↑ 2.85%
FY20Y/Y Change
Total Assets
13.6B
↑ 17.88%
Total Liabilities
9.8B
↑ 11.3%
FY21Y/Y Change
Total Assets
13.9B
↑ 2.14%
Total Liabilities
9.4B
↓ 4.88%
FY22Y/Y Change
Total Assets
14.9B
↑ 7.37%
Total Liabilities
10.5B
↑ 12.46%
FY23Y/Y Change
Total Assets
14.3B
↓ 4.28%
Total Liabilities
9.3B
↓ 11.66%
Q4 FY22Q/Q Change
Total Assets
14.9B
↑ 9.15%
Total Liabilities
10.5B
↑ 16.76%
Q1 FY23Q/Q Change
Total Assets
13.8B
↓ 7.85%
Total Liabilities
9.3B
↓ 11.97%
Q2 FY23Q/Q Change
Total Assets
13.7B
↓ 0.04%
Total Liabilities
9.1B
↓ 1.46%
Q3 FY23Q/Q Change
Total Assets
14.1B
↑ 2.6%
Total Liabilities
9.0B
↓ 1.05%
Q4 FY23Q/Q Change
Total Assets
14.3B
↑ 1.28%
Total Liabilities
9.3B
↑ 2.91%
Q1 FY24Q/Q Change
Total Assets
14.3B
↑ 0.43%
Total Liabilities
9.3B
↑ 0.01%
FY18Y/Y Change
Operating Cash Flow
1.8B
↑ 32.99%
Investing Cash Flow
-2.3B
↑ 736.67%
Financing Cash Flow
533.0M
↓ 312.35%
FY19Y/Y Change
Operating Cash Flow
1.8B
↑ 0.28%
Investing Cash Flow
-504.0M
↓ 77.69%
Financing Cash Flow
-951.0M
↓ 278.42%
FY20Y/Y Change
Operating Cash Flow
2.1B
↑ 18.44%
Investing Cash Flow
-572.0M
↑ 13.49%
Financing Cash Flow
123.0M
↓ 112.93%
FY21Y/Y Change
Operating Cash Flow
2.2B
↑ 4.09%
Investing Cash Flow
-458.0M
↓ 19.93%
Financing Cash Flow
-1.9B
↓ 1613.82%
FY22Y/Y Change
Operating Cash Flow
1.9B
↓ 13.6%
Investing Cash Flow
-883.0M
↑ 92.79%
Financing Cash Flow
-904.0M
↓ 51.45%
Q4 FY22Q/Q Change
Operating Cash Flow
741.0M
↑ 40.87%
Investing Cash Flow
-438.0M
↑ 253.23%
Financing Cash Flow
780.0M
↓ 247.45%
Q1 FY23Q/Q Change
Operating Cash Flow
549.0M
↓ 25.91%
Investing Cash Flow
-216.0M
↓ 50.68%
Financing Cash Flow
-1.8B
↓ 331.03%
Q2 FY23Q/Q Change
Operating Cash Flow
183.0M
↓ 66.67%
Investing Cash Flow
-80.0M
↓ 62.96%
Financing Cash Flow
-494.0M
↓ 72.59%
Q3 FY23Q/Q Change
Operating Cash Flow
724.0M
↑ 295.63%
Investing Cash Flow
-567.0M
↑ 608.75%
Financing Cash Flow
-416.0M
↓ 15.79%

Technicals Summary

Sell

Neutral

Buy

Zoetis Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Zoetis Inc.
Zoetis Inc.
-2.67%
-13.6%
-1.0%
-9.87%
48.99%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-4.61%
10.66%
35.96%
31.71%
57.73%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.0%
4.03%
2.16%
14.98%
14.98%
Viatris Inc.
Viatris Inc.
-6.39%
-3.66%
1.48%
-28.5%
-37.21%
Catalent, Inc.
Catalent, Inc.
-0.25%
24.87%
26.05%
-50.05%
2.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Zoetis Inc.
Zoetis Inc.
32.69
32.69
2.58
5.76
0.5
0.14
0.01
11.07
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
35.56
35.56
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
28.2
28.2
1.69
0.46
0.07
0.04
0.03
1.8
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.22
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Zoetis Inc.
Zoetis Inc.
Buy
$77.4B
48.99%
32.69
27.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.2B
57.73%
35.56
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.6B
14.98%
28.2
9.64%
Viatris Inc.
Viatris Inc.
Hold
$12.0B
-37.21%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.0B
2.97%
211.02
-28.44%

Institutional Holdings

  • Vanguard Group Inc

    8.93%
  • BlackRock Inc

    8.05%
  • State Street Corporation

    4.29%
  • State Farm Mutual Automobile Ins Co

    3.54%
  • Bank of America Corp

    3.06%
  • Morgan Stanley - Brokerage Accounts

    2.82%

Corporate Announcements

  • Zoetis Inc. Dividends March,2024

    In the quarter ending March,2024. Zoetis Inc. has declared dividend of $0.43

    Read More

Company Information

Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.

Organization
Zoetis Inc.
Employees
14100
CEO
Ms. Kristin C. Peck
Industry
Health Technology

FAQs